Korean-American Julie Kim Becomes First Female CEO of Japan's Largest Pharmaceutical Firm, Takeda
Julie Kim, a Korean-American, has been appointed as the new Chief Executive Officer (CEO) of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical firm. This marks the first time in Takeda's 245-year history that a woman has become CEO.
According to the Nihon Keizai Shimbun (Nikkei) on June 26, Kim assumed her new role as CEO of Takeda Pharmaceutical on June 24.
Kim was born in Seoul in 1970 and immigrated to the United States as a child, making her a 1.5-generation Korean American. She majored in economics at Dartmouth College and earned an MBA from the J.L. Kellogg School of Management at Northwestern University.
She built her career in the pharmaceutical industry, focusing primarily on marketing, where she was responsible for market analysis and strategic planning. She is also a former executive of Shire, an Irish pharmaceutical company that was acquired by Takeda Pharmaceutical in 2019.
At a press conference held on June 25, Kim expressed her ambition for Takeda to lead the transformation into a biopharmaceutical company utilizing artificial intelligence (AI) and advanced technologies.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
As the entire pharmaceutical industry seeks to leverage AI and new technologies to reshape research and development and business structures, Kim stated her vision for positioning Takeda at the forefront of this change.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.